We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The National Institutes of Health (NIH) has begun enrolling adults and children in a phase 3 clinical trial to test the effectiveness of the smallpox antiviral TPOXX (tecovirimat) on monkeypox. Read More
Merck’s blockbuster drug Keytruda (pembrolizumab) may be approved to treat 17 different kinds of cancer, but the monoclonal antibody doesn’t always hit it out of the park. Read More
Last week’s Paris meeting of the European Society of Medical Oncology (ESMO) featured a hit and a miss in renal cell cancer and some good news for elderly patients who can’t take platinum-based chemo regimens for non-small cell lung cancer (NSCL). Read More
Regeneron and Bayer’s blockbuster Eylea (aflibercept) given in three- or four-month intervals demonstrated efficacy against two major eye diseases in a pair of late-stage studies, giving the drugmakers an edge in an increasingly competitive market. Read More
Two late-breaking phase 3 studies highlighted advances in breast and colorectal cancer at the annual meeting of the European Society of Medical Oncology in Paris this week. Read More
UCB Pharma is going big with open-label extension data showing that almost 90 percent of plaque psoriasis patients who responded to Bimzelx (bimekizumab) maintained clear skin after three years of treatment. Read More
Sarepta Therapeutics’ trial of its Duchenne muscular dystrophy drug candidate is back on track four months after the FDA stopped it when a trial participant experienced a serious adverse event (SAE) that could have been life-threatening. Read More
Futura Medical’s MED3000, a drug-free topical gel for treating erectile dysfunction (ED), stood up well against Cialis (tadalafil) in a phase 3 study that could ultimately lead to the first over-the-counter ED product in the U.S. Read More
Amgen’s oral chemotherapy sotorasib significantly improved progression-free survival relative to intravenous docetaxel in patients with previously treated KRAS G12C-mutated nonsmall-cell lung cancer (NSCLC) in a late-stage study. Read More
A narrowly missed primary endpoint didn’t prevent Bayer from touting a phase 3 win for Kerendia (finerenone) as a cardioprotective agent for people with late-stage chronic kidney disease and type 2 diabetes. Read More